Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impactsa report from the 25th Annual Harvard Nutrition Obesity Symposium The American Journal of Clinical Nutrition Triple Agonism Based Therapies for Obesity Current Cardiovascular Risk Reports Springer Nature Link Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News What is the dose of Cagrisema (Pegvisomant)? Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination